Last checked at 21 May 2024 07:00
21 May 2024
Scancell Holdings plc
("Scancell" or the "Company")
Issue of share options
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer, announces that on 20 May 2024 it has granted share options to acquire ordinary shares of 0.1 pence each in the capital of the Company to Sath Nirmalananthan, CFO and Executive Director.
These share options have an exercise price of 10.1pence each, the closing share price on 20 May 2024, and will vest over three years in three equal tranches from 29 August 2024 with no vesting criteria other than to remain in employment. Any unexercised share options which are being granted per the above will expire at 6pm on 19 May 2034.
The Board of Scancell approved the issuance of share option grants to incentivise and retain directors and staff of the Company. The Board considered both historical practices and on-going funding requirements in this regard.
Related Party Transaction
The issue of share options to Sath Nirmalananthan are deemed to be a related party transaction pursuant to AIM Rule 13 of the AIM Rules for Companies. The Company's directors who are independent of the related party transaction, being all the directors other than Sath Nirmalananthan, consider, having consulted with the Company's Nominated Adviser, Stifel Nicolaus Europe Limited, that the terms of the related party transactions are fair and reasonable insofar as the shareholders of the Company are concerned.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name | Sath Nirmalananthan |
2 | Reason for the notification | |
a) | Position/status | Chief Financial Officer and PDMR |
b) | Initial notification/Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Scancell Holdings plc |
b) | LEI | 2138008RXEG856SNP666 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument | Options to acquire ordinary shares |
b) | Identification Code | GB00B63D3314 |
c) | Nature of the transaction | Grant of options to acquire ordinary shares |
d) | Price(s) and volume(s) | 1,000,000 share options 10.1 pence per share option |
e) | Aggregated information - Aggregated volume - Price |
N/A (single transaction)
|
f) | Date of the transaction | 20 May 2024 |
g) | Place of the transaction | Outside a trading venue |
For further information, please contact: | |
Scancell Holdings plc | +44 (0) 20 3709 5700 |
Professor Lindy Durrant, CEO Dr Jean-Michel Cosséry, Non-Executive Chairman | |
Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker) | +44 (0) 20 7710 7600 |
Nicholas Moore/Samira Essebiyea (Healthcare Investment Banking) Nick Harland (Corporate Broking) | |
WG Partners LLP (Joint Broker) | +44(0) 20 3705 9330 |
David Wilson/Claes Spang/Sathesh Nadarajah/Erland Sternby | |
Panmure Gordon (UK) Limited (Joint Broker) | +44 (0) 20 7886 2500 |
Freddy Crossley/Emma Earl (Corporate Finance) Rupert Dearden (Corporate Broking) | |
Consilium Strategic Communications | +44 (0) 20 3709 5700 |
Mary-Jane Elliott/Angela Gray/Lindsey Neville | scancell@consilium-comms.com
|
About Scancell
Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope® and ImmunoBody® for vaccines and GlyMab® and AvidiMab® for antibodies.
Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company's unique approach is that its innovative products target modifications of proteins and lipids. For the vaccines (Moditope® and ImmunoBody®) this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab®) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab®).
For further information about Scancell, please visit: https://www.scancell.co.uk/